Page 60 - 86_01
P. 60
ANALES
RANF
www.analesranf.com
thopoxviruses. Virology. 1998;244(2):365-96. 51.
6. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. 21. Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr
NYVAC: a highly attenuated strain of vaccinia virus. Virology. Opin HIV AIDS. 2019;14(3):153-60.
1992;188(1):217-32. 22. Excler JL, Kim JH. Novel prime-boost vaccine strategies against HIV-1.
7. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified
vaccinia virus Ankara replicates in baby hamster kidney cells, a potential Expert Rev. Vaccines. 2019;18(8):765-79.
host for virus propagation, but not in various human transformed and pri- 23. Li S, Rodrigues M, Rodríguez D, Rodríguez JR, Esteban M, Palese P, et al.
mary cells. J Gen Virol. 1998;79 ( Pt 2):347-52.
8. Nájera JL, Gómez CE, Domingo-Gil E, Gherardi MM, Esteban M. Cellular Priming with recombinant influenza virus followed by administration of re-
and biochemical differences between two attenuated poxvirus vaccine can- combinant vaccinia virus induces CD8+ T-cell-mediated protective immu-
didates (MVA and NYVAC) and role of the C7L gene. J. Virol.. nity against malaria. Proc. Natl. Acad. Sci. USA. 1993;90(11):5214-8.
2006;80(12):6033-47. 24. Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, et al.
9. Sancho MC, Schleich S, Griffiths G, Krijnse-Locker J. The block in assembly Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine
of modified vaccinia virus Ankara in HeLa cells reveals new insights into candidates based on the attenuated poxvirus strains MVA and NYVAC co-
vaccinia virus morphogenesis. J Virol. 2002;76(16):8318-34. expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-
10. Gallego-Gómez JC, Risco C, Rodríguez D, Cabezas P, Guerra S, Carrascosa Pol-Nef proteins of clade B. Vaccine. 2007;25(15):2863-85
JL, et al. Differences in virus-induced cell morphology and in virus matu- 25. Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, et al. Generation
ration between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-
virus in infected human cells. J. Virol. 2003;77(19):10606-22. 1 Env/Gag-Pol-Nef antigens of clade C. Vaccine. 2007;25(11):1969-92
11. Guerra S, Nájera JL, González JM, López-Fernández LA, Climent N, Gatell 26. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, et al. An env
JM, et al. Distinct gene expression profiling after infection of immature gene derived from a primary human immunodeficiency virus type 1 isolate
human monocyte-derived dendritic cells by the attenuated poxvirus vectors confers high in vivo replicative capacity to a chimeric simian/human im-
MVA and NYVAC. J. Virol. 2007;81(16):8707-21. munodeficiency virus in rhesus monkeys. J. Virol. 1996;70(5):3198-206.
12. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Limbach K, Norton EK, et 27. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaf-
al. Vaccinia virus host range genes. Virology. 1990;179(1):276-86. ten P, Baak I, et al. Differential CD4+ versus CD8+ T-cell responses eli-
13. Oguiura N, Spehner D, Drillien R. Detection of a protein encoded by the cited by different poxvirus-based human immunodeficiency virus type 1
vaccinia virus C7L open reading frame and study of its effect on virus mul- vaccine candidates provide comparable efficacies in primates. J. Virol.
tiplication in different cell lines. J. Gen. Virol. 1993;74 ( Pt 7):1409-13. 2008;82(6):2975-88.
14. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recog- 28. Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-
nition receptors and the innate immune response to viral infection. Viruses. Sanz R, et al. Removal of vaccinia virus genes that block interferon type I
2011;3(6):920-40. and II pathways improves adaptive and memory responses of the HIV/AIDS
15. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, vaccine candidate NYVAC-C in mice. J. Virol. 2012;86(9):5026-38.
Akira S, et al. Innate immune sensing of modified vaccinia virus Ankara 29. Delaloye J, Filali-Mouhim A, Cameron MJ, Haddad EK, Harari A, Goulet
(MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. JP, et al. Interleukin-1- and type I interferon-dependent enhanced immu-
PLoS Pathogens. 2009;5(6):e1000480. nogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual
16. Smith GL, Law M. The exit of vaccinia virus from infected cells. Virus Res. deletions of type I and type II interferon-binding proteins. J. Virol.
2004;106(2):189-97. 2015;89(7):3819-32.
17. Sadikot RT, Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc. 30. Gómez CE, Perdiguero B, Sánchez-Corzo C, Sorzano COS, Esteban M. Im-
2005;2(6):537-40, 11-2. mune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of
18.Perdiguero B, Gómez CE, Esteban M. Bioluminescence Imaging as a Tool Viral Genes that Act on Several Signalling Pathways. Viruses. 2017;10(1).
for Poxvirus Biology. Methods in molecular biology (Clifton, NJ). 31. Perdiguero B, Gómez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, et
2019;2023:269-85. al. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of
19. Gómez CE, Nájera JL, Domingo-Gil E, Ochoa-Callejero L, González-Ase- TLR signalling, is an effective approach to enhance the immunogenicity in
guinolaza G, Esteban M. Virus distribution of the attenuated MVA and mice of the HIV/AIDS vaccine candidate NYVAC-C. PloS one.
NYVAC poxvirus strains in mice. J. gen- Virol. 2007;88(Pt 9):2473-8. 2013;8(9):e74831.
20. Corbett M, Bogers WM, Heeney JL, Gerber S, Genin C, Didierlaurent A, et 32. Di Pilato M, Mejías-Pérez E, Zonca M, Perdiguero B, Gómez CE, Trakala
al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, M, et al. NFkappaB activation by modified vaccinia virus as a novel strategy
simple, and immunogenic. Proc. Natl. Acad. Sci. USA. 2008;105(6):2046- to enhance neutrophil migration and HIV-specific T-cell responses. Proc.
Natl. Acad. Sci. USA. 2015;112(11):E1333-42.
33. García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra
MVA-B como candidato vacunal frente al VIH/SIDA: de la inves-
58 tigación básica a los ensayos clínicos profiláctico y terapéutico.
Carmen Elena Gómez Rodríguez
An Real Acad Farm Vol. 86. Nº 1 (2020) · pp. 29 -60
